[go: up one dir, main page]

MX386895B - Formulaciones oculares para suministro de farmaco al segmento posterior del ojo - Google Patents

Formulaciones oculares para suministro de farmaco al segmento posterior del ojo

Info

Publication number
MX386895B
MX386895B MX2018014122A MX2018014122A MX386895B MX 386895 B MX386895 B MX 386895B MX 2018014122 A MX2018014122 A MX 2018014122A MX 2018014122 A MX2018014122 A MX 2018014122A MX 386895 B MX386895 B MX 386895B
Authority
MX
Mexico
Prior art keywords
eye
posterior segment
drug
delivery
ocular formulations
Prior art date
Application number
MX2018014122A
Other languages
English (en)
Inventor
David P Bingaman
Martin B Wax
Paul G Chaney
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of MX386895B publication Critical patent/MX386895B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere con formulaciones tópicas que comprenden un compuesto de la siguiente formula: (ver formula) para tratar la neovascularizacion ocular; el Compuesto I esta presente en una solución o una suspensión en aproximadamente 0.005% a aproximadamente 5.0% p/v, de manera que la solución 15 o suspensión suministre el compuesto al segmento posterior del ojo para inhibir el VEGF en la retina y/o el coroide.
MX2018014122A 2013-03-14 2014-03-14 Formulaciones oculares para suministro de farmaco al segmento posterior del ojo MX386895B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784681P 2013-03-14 2013-03-14
PCT/US2014/027589 WO2014152661A1 (en) 2013-03-14 2014-03-14 Ocular formulations for drug-delivery to the posterior segment of the eye

Publications (1)

Publication Number Publication Date
MX386895B true MX386895B (es) 2025-03-19

Family

ID=50625096

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018014122A MX386895B (es) 2013-03-14 2014-03-14 Formulaciones oculares para suministro de farmaco al segmento posterior del ojo
MX2015012653A MX360888B (es) 2013-03-14 2014-03-14 Formulaciones oculares para suministro de fármaco al segmento posterior del ojo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015012653A MX360888B (es) 2013-03-14 2014-03-14 Formulaciones oculares para suministro de fármaco al segmento posterior del ojo.

Country Status (22)

Country Link
US (8) US9446026B2 (es)
EP (2) EP3520773A1 (es)
JP (3) JP6542193B2 (es)
KR (2) KR102433489B1 (es)
CN (2) CN105142686B (es)
AU (3) AU2014239252B2 (es)
BR (1) BR112015021334B1 (es)
CA (1) CA2900840C (es)
DK (1) DK2968650T3 (es)
ES (1) ES2710152T3 (es)
HU (1) HUE042528T2 (es)
IL (2) IL240510B (es)
MX (2) MX386895B (es)
PH (2) PH12015501938B1 (es)
PL (1) PL2968650T3 (es)
PT (1) PT2968650T (es)
RU (2) RU2665953C2 (es)
SA (1) SA516380321B1 (es)
SG (2) SG11201507316UA (es)
TR (1) TR201901462T4 (es)
WO (1) WO2014152661A1 (es)
ZA (2) ZA201505447B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2883003C (en) 2012-09-12 2021-11-16 Novaliq Gmbh Semifluorinated alkane compositions
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US9814702B2 (en) 2014-09-17 2017-11-14 Panoptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
MX2018010997A (es) 2016-03-11 2019-07-04 Georgia Pacific Gypsum Llc Paneles de yeso, sistemas y metodos.
WO2018193093A1 (en) * 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
RU2652342C1 (ru) * 2017-07-13 2018-04-25 Наталья Александровна Гаврилова Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
AT522609B1 (de) 2019-05-28 2022-06-15 Miba Frictec Gmbh Reibvorrichtung
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
JP2022548071A (ja) * 2019-09-13 2022-11-16 アメリカ合衆国 網膜変性を治療するための新薬の開発につながる標的
KR20240017423A (ko) 2021-05-03 2024-02-07 아빌라 테라퓨틱스, 인크. 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물
WO2025058571A1 (en) * 2023-09-15 2025-03-20 Agency For Science, Technology And Research Polymer composition comprising a thermogelling polymer and a tyrosine kinase inhibitor, and related methods thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891913A (en) 1994-10-10 1999-04-06 Novartis Finance Corporation Ophthalmic and aural compositions containing diclofenac potassium
JPH10203960A (ja) * 1997-01-24 1998-08-04 Ofutekusu:Kk 点眼液組成物
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
EP1213018A4 (en) 1999-09-06 2004-04-14 Ono Pharmaceutical Co AGENTS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES
HUP0302553A3 (en) * 2000-11-28 2009-03-30 Pfizer Prod Inc Salts of a isothiazole-4-carboxamide and process for their preparation and use for the preparation of anti-hyperproliferation agents
AU2003281664A1 (en) * 2002-07-25 2004-02-16 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
US20050007449A1 (en) * 2002-08-29 2005-01-13 Kazuyoshi Ikado Vision aid network server, vision aid network system, vision aid method, vision aid system, color sense function reporting, program for reporting color sense function, method for reporting color sense function, color sense aid system, color sense aid program, and color sense aid method
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
US7483533B2 (en) * 2004-08-05 2009-01-27 King Fahd University Of Petroleum Elliptic polynomial cryptography with multi x-coordinates embedding
JP2006111621A (ja) 2004-09-15 2006-04-27 Santen Pharmaceut Co Ltd ピレノキシン懸濁型点眼剤
CA2586074C (en) * 2004-11-09 2013-07-23 Novagali Pharma Sa Ophthalmic oil-in-water type emulsion with stable positive zeta potential
BRPI0606172A2 (pt) * 2005-06-08 2009-06-02 Targegen Inc métodos e composições para o tratamento de distúrbios oculares
JP2007011785A (ja) * 2005-06-30 2007-01-18 Toshiba Corp 情報処理装置、およびタッチパネルの振動制御方法
JP2007012937A (ja) * 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
JP5247453B2 (ja) * 2005-10-10 2013-07-24 ノバガリ ファルマ エスア プロスタグランジン含有眼科用カチオン性水中油型エマルジョン
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20080280890A1 (en) * 2007-02-22 2008-11-13 Ghanshyam Patil Hydroxylamine compounds and methods of their use
PL391002A1 (pl) * 2007-08-09 2010-10-25 Senju Pharmaceutical Co, Ltd Dwuskładnikowe krople do oczu zawierające pirenoksynę
WO2010004435A2 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
JP2010265261A (ja) 2009-04-17 2010-11-25 Santen Pharmaceut Co Ltd レボカバスチン懸濁型点眼剤
JP2012250918A (ja) 2011-05-31 2012-12-20 Rohto Pharmaceutical Co Ltd ニューキノロン剤含有水性組成物
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent

Also Published As

Publication number Publication date
KR102433489B1 (ko) 2022-08-17
CA2900840A1 (en) 2014-09-25
BR112015021334B1 (pt) 2020-04-07
JP6542193B2 (ja) 2019-07-10
SG10201710928PA (en) 2018-02-27
JP2016517427A (ja) 2016-06-16
SG11201507316UA (en) 2015-10-29
IL276016B (en) 2022-04-01
EP2968650B1 (en) 2019-01-16
CA2900840C (en) 2023-03-28
ZA201505447B (en) 2022-06-29
CN105142686B (zh) 2020-04-10
BR112015021334A2 (pt) 2017-07-18
US10092549B2 (en) 2018-10-09
RU2015143898A (ru) 2017-04-19
PH12019501902A1 (en) 2021-03-01
US20240325357A1 (en) 2024-10-03
AU2017210543A1 (en) 2017-08-17
RU2018128980A3 (es) 2022-01-11
US10307404B1 (en) 2019-06-04
PH12015501938B1 (en) 2019-11-13
HK1216236A1 (en) 2016-10-28
WO2014152661A1 (en) 2014-09-25
DK2968650T3 (en) 2019-03-11
ZA201907176B (en) 2022-12-21
EP3520773A1 (en) 2019-08-07
AU2019202857B2 (en) 2021-02-18
IL276016A (en) 2020-08-31
HUE042528T2 (hu) 2019-07-29
CN111789814A (zh) 2020-10-20
RU2665953C2 (ru) 2018-09-05
IL240510B (en) 2020-08-31
US20140303219A1 (en) 2014-10-09
AU2014239252B2 (en) 2017-07-06
MX2015012653A (es) 2016-08-18
PH12015501938A1 (en) 2016-01-11
US20190183864A1 (en) 2019-06-20
MX360888B (es) 2018-11-20
US20160354349A1 (en) 2016-12-08
RU2018128980A (ru) 2018-11-05
CN111789814B (zh) 2022-07-19
IL240510A0 (en) 2015-10-29
RU2768489C2 (ru) 2022-03-24
SA516380321B1 (ar) 2019-01-16
PT2968650T (pt) 2019-02-12
KR20210132205A (ko) 2021-11-03
US20190247368A1 (en) 2019-08-15
US20160022646A1 (en) 2016-01-28
KR20150127256A (ko) 2015-11-16
PL2968650T3 (pl) 2019-05-31
JP2022009275A (ja) 2022-01-14
US9446026B2 (en) 2016-09-20
ES2710152T3 (es) 2019-04-23
JP6965308B2 (ja) 2021-11-10
CN105142686A (zh) 2015-12-09
AU2019202857A1 (en) 2019-05-16
JP2019167377A (ja) 2019-10-03
US20190240201A1 (en) 2019-08-08
US20210196690A1 (en) 2021-07-01
EP2968650A1 (en) 2016-01-20
AU2014239252A1 (en) 2015-08-13
TR201901462T4 (tr) 2019-02-21
AU2017210543B2 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MY171920A (en) Prevention and treatment of ocular conditions
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MY198195A (en) Composition For Suppressing Or Improving Eye Fatigue
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
MX391658B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
PH12015501555A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
MX2018003799A (es) Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla.
TW201613596A (en) Ophthalmic suspension preparation
EP3187179A4 (en) Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient
EP2962691A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE POSTERIOR PART OF THE IL CONTAINING A TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS ACTIVE INGREDIENT
GR1008505B (el) Οφθαλμικο φαρμακευτικο σκευασμα ελευθερο συντηρητικου περιεχον δορζολαμιδη και τιμολολη
GR1008509B (el) Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δορζολαμιδη